Trial Profile
The efficacy of ramelteon, selective melatonin receptor agonist, during the critical care: MELIt Trial (Melatonin Evaluation of Lowered Inflammation in ICU Trial)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 May 2017
Price :
$35
*
At a glance
- Drugs Ramelteon (Primary)
- Indications Delirium; Inflammation
- Focus Therapeutic Use
- Acronyms MELIt Trial
- 19 May 2017 Status changed from recruiting to completed.
- 18 Aug 2015 According to the University Hospital Medical Information Network - Japan record, status changed from not yet recruiting to recruiting.
- 04 Mar 2015 New trial record